Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries

I would like to take this opportunity to express my deepest gratitude to everyone who responded to my study entitled: “Trouble Spots in Online DirecttoConsumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.”1 Scholars from several different fields, including medical science, pharmacy, business, and communication have all participated in the discussion of current issues and the future of directto consumer advertising (DTCA), bringing multifaceted viewpoints to bear on prescription drug marketing based on their own disciplines.